BeyondSpring
  • About
    • Who We Are
    • Management Team
    • Scientific Advisors
    • Board of Directors
  • Pipeline & Research
    • Pipeline
    • Plinabulin
    • Protein Degradation
    • Other Pipeline
    • Posters & Publications
    • Collaborations
    • Expanded Access Policy
  • NEWS & MEDIA
  • Investors
    • Stock Overview
    • Events & Presentations
    • Financials & Filings
    • ESG
    • Corporate Governance
  • Careers
  • Contact Us
Select Page

Society for Immunotherapy of Cancer (SITC) Annual Meeting (2019)

July 14, 2020

11.09.2019

Society for Immunotherapy of Cancer (SITC) Annual Meeting (2019)

Validation of a Single-Blinded (Patients Only) Study Design for the Prevention of Premature Patient Consent Withdrawal in the Immuno-Oncology Trial DUBLIN-3

RECENT NEWS ARTICLES

  • BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
  • BeyondSpring Files 2022 Annual Report on Form 20-F
  • BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
  • BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
  • BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules
  • BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
  • BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
  • BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022
  • BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting
  • BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting

RECENT MEDIA COVERAGE

  • TD Ameritrade Watch List
  • Managing Chemotherapy Toxicities for Improved Patient Outcomes
  • New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
  • Seed Therapeutics blossoms in an $800M deal with Lilly
  • Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
  • BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
  • JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
  • Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
  • Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
  • Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring
Investor Contact
IR@beyondspringpharma.com
Media Contact
PR@beyondspringpharma.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

ABOUT

  • Who We Are
  • Management Team
  • Scientific Advisors
  • Board of Directors

PIPELINE & RESEARCH

  • Pipeline Overview
  • Plinabulin
  • Protein Degradation
  • Other Pipeline
  • Posters & Publications
  • Collaboration
  • Expanded Access Policy

INVESTORS

  • Stock Overview
  • Events & Presentations
  • Financials & Filings
  • Corporate Governance

CAREERS

  • Job Opportunities

NEWS & MEDIA

  • Press Releases
  • Media Coverage
BeyondSprings Inc LinkedIn   BeyondSprings Inc Twitter

BeyondSprings Inc LinkedIn      BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved.   Privacy Notice   |   Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.OkPrivacy policy